A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.

Abstract

BACKGROUND:

The efficacy and safety of bimatoprost ophthalmic solution 0.03% for treating hypotrichosis were shown in a randomized controlled trial and in an open-label study. To date, no data on real-world experience have been published.

OBJECTIVE:

To evaluate long-term patient satisfaction, usage patterns, and safety of bimatoprost 0.03% in clinical practice.

MATERIALS AND METHODS:

In this retrospective chart review with a cross-sectional design, adult patients exposed to bimatoprost 0.03% for at least 12 months were randomly sampled from 16 investigational sites. Charts were reviewed for medication usage characteristics and adverse events (AEs). At a study visit, questionnaires eliciting patient-reported outcomes were administered and spontaneously reported AEs were tabulated.

RESULTS:

Analysis included 585 subjects with a mean (SD) treatment duration of 19.3 (4.3) months. Patient satisfaction with bimatoprost 0.03% was 92.5%; on average, approximately 3 applications per week maintained benefits. Overall, 27.4% of patients spontaneously recalled experiencing AEs while on treatment; however, patient charts showed that only 4 AEs were documented. No instances of iris hyperpigmentation occurred. No serious or severe AEs were noted.

CONCLUSION:

Treatment with bimatoprost 0.03% for at least 12 months is safe, and long-term use is associated with a high degree of satisfaction.

• Authors: Steven G Yoelin, Steven Fagien, Sue Ellen Cox, Paula G Davis, Antoinette Campo, Carrie A Caulkins, Conor J Gallagher
• Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (Dermatol Surg) Vol. 40 Issue 10 Pg. 1118-24 (Oct 2014) ISSN: 1524-4725 [Electronic] United States
• PMID: 25229783 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Amides
• Ophthalmic Solutions
• Cloprostenol
• Bimatoprost

Topics

• Adult
• Amides (adverse effects, therapeutic use)
• Bimatoprost
• Cloprostenol (adverse effects, analogs & derivatives, therapeutic use)
• Cross-Sectional Studies
• Erythema (chemically induced)
• Eyelashes
• Eyelid Diseases (chemically induced)
• Female
• Humans
• Hypotrichosis (drug therapy)
• Male
• Middle Aged
• Ophthalmic Solutions (adverse effects, therapeutic use)
• Patient Satisfaction
• Pigmentation Disorders (chemically induced)
• Pruritus (chemically induced)
• Retrospective Studies
• Treatment Outcome